Prevalence of Prostate Disease in Men Attending Urology Clinic at Federal Medical Centre Makurdi Using PSA as a Marker

Prostate diseases remain a major public health concern worldwide, particularly among aging male populations. This study investigated the prevalence and associated risk factors of prostate disease in men attending the Urology Clinic at the Federal Medical Centre, Makurdi, Benue State, Nigeria, using serum prostate-specific antigen (PSA) levels as a diagnostic marker. A total of 100 male participants aged 50 years and above were recruited for PSA testing, while 200 participants completed structured questionnaires on demographic and lifestyle characteristics. Serum PSA levels were determined using enzyme-linked immunosorbent assay (ELISA). Elevated PSA was defined as ≥4.0 ng/mL. Elevated PSA levels were observed in 60% of participants tested, with the highest prevalence among the Hausa (33.3%) and Tiv (30%) ethnic groups, and in men aged 60–69 years (55%). Questionnaire data indicated that 66% of respondents reported a history of prostate disease, and 61% had a family history of the condition. Bacterial infections (45%) and diabetes mellitus (30.5%) were the most frequently reported comorbidities. The findings demonstrate a substantial burden of prostate disease among men in Makurdi, highlighting age, family history, and comorbidities as key risk factors. Routine PSA screening, particularly among high-risk groups, is recommended for early detection and intervention.

Prostate, Cancer, Disease, Urology, public health.

1. American Cancer Society. (2011). Cancer facts and figures 2011. American Cancer Society. [Google Scholar] [Crossref]

2. Basch, E., Oliver, T. K., Vickers, A., Thompson, I., Kantoff, P., Parnes, H., … & Loblaw, D. A. (2015). Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. Journal of Clinical Oncology, 30(24), 3020–3025. [Google Scholar] [Crossref]

3. Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blazina, I., Fu, R., … & Lin, K. (2011). Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 155(11), 762–771. [Google Scholar] [Crossref]

4. Cooper, R. S., Tettey, Y., Benneh, A. A., Boateng, E., & Plange-Rhule, J. (2013). Prostate cancer in sub-Saharan Africa: evolving role of PSA measurement. African Journal of Urology, 19(4), 151–157. [Google Scholar] [Crossref]

5. Grönberg, H. (2003). Prostate cancer epidemiology. The Lancet, 361(9360), 859–864. [Google Scholar] [Crossref]

6. Hsing, A. W., & Chokkalingam, A. P. (2006). Prostate cancer epidemiology. Frontiers in Bioscience, 11, 1388–1413. [Google Scholar] [Crossref]

7. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A., & Lieber, M. M. (1993). Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA, 270(7), 860–864. [Google Scholar] [Crossref]

8. Adejumo, O. A., Ogunkoya, O. A., Rufai, A., & Adeigbe, A. C. (2019). Prostate cancer and benign prostatic hyperplasia in Ekiti State, Nigeria: a hospital-based study. African Journal of Urology, 25(1), 1–6. [Google Scholar] [Crossref]

9. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. [Google Scholar] [Crossref]

10. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., & Ratliff, T. L. (1994). Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer. Journal of Urology, 151(5), 1283–1290. [Google Scholar] [Crossref]

11. Chu, L. W., Ritchey, J., Devesa, S. S., Quraishi, S. M., Zhang, H., & Hsing, A. W. (2011). Prostate cancer incidence rates in Africa. Prostate Cancer, 2011, 947870. [Google Scholar] [Crossref]

12. Ekwere, P. D., Egbe, S. N., Akpan, E. E., & Oku, A. I. (2012). Epidemiology of prostate cancer in Uyo, Nigeria. International Journal of Urology, 19(1), 44–49. [Google Scholar] [Crossref]

13. Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer, 144(8), 1941–1953. [Google Scholar] [Crossref]

14. Giovannucci, E., Liu, Y., Platz, E. A., Stampfer, M. J., & Willett, W. C. (2007). Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-up Study. International Journal of Cancer, 121(7), 1571–1578. [Google Scholar] [Crossref]

15. Ibeziako, S. N., Obianwu, I., & Eke, N. (2021). Prostate specific antigen and prostate diseases in men attending a tertiary health facility in Port Harcourt, Nigeria. Nigerian Journal of Medicine, 30(2), 127–133. [Google Scholar] [Crossref]

16. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90. [Google Scholar] [Crossref]

17. Kehinde, E. O., Mojiminiyi, O. A., Sheikh, M., Anim, J. T., & Abdeen, S. (2005). Age-specific reference levels of serum prostate-specific antigen (PSA) and PSA density in healthy Arab men. BJU International, 96(7), 994–998. [Google Scholar] [Crossref]

18. Levi, F., Lucchini, F., Negri, E., & La Vecchia, C. (2004). Prostate cancer mortality in Europe and the United States: a comparison of trends. European Journal of Cancer, 40(10), 1490–1496. [Google Scholar] [Crossref]

19. Nwofor, A. M. E., & Oranusi, C. K. (2004). Prostate specific antigen (PSA) screening for prostatic cancer: experience at Nnewi, South-East Nigeria. African Journal of Urology, 10(2), 107–111. [Google Scholar] [Crossref]

20. Platz, E. A., Rimm, E. B., Willett, W. C., Kantoff, P. W., & Giovannucci, E. (2000). Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. Journal of the National Cancer Institute, 92(24), 2009–2017. [Google Scholar] [Crossref]

21. Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., Bull, D., & Million Women Study Collaborators. (2007). Cancer incidence and mortality in relation to body mass index in the Million Women Study. BMJ, 335(7630), 1134. [Google Scholar] [Crossref]

22. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New England Journal of Medicine, 317(15), 909–916. [Google Scholar] [Crossref]

23. Ukoli, F. A., Osime, U., Akereyeni, F., Okonofua, F., Gashti, C. N., & Landis, P. (2003). Prevalence of elevated serum prostate-specific antigen in rural Nigeria. International Journal of Urology, 10(6), 315–322. [Google Scholar] [Crossref]

• Migrant Health in Morocco: Between Law and Reality
• CaknaMinda: An Educator-Centred Mobile App for Early Screening of Mental Health and Schizophrenia Risks
• Health System and Nursing Strategies for Enhancing Male Participation in Family Planning: Evidence from Tema General Hospital, Ghana.
• From Īśvara-Praṇidhāna to Parā-Bhakti: Convergent Paths of Aṣṭāṅga Yoga and Bhakti Yoga
• Evidence-Based Psycho-Oncological Interventions: A Multimodal Approach to Supportive Care